Reestablishment of Active Immunity against HBV Graft Reinfection after Liver Transplantation for HBV-Related End Stage Liver Disease
Background. The aim of this study was to establish a hepatitis B virus (HBV) vaccination protocol among orthotopic liver transplantation (OLT) recipients under the coverage of a low-dose hepatitis B immunoglobulin (HBIG) combined with an antiviral agent prophylaxis protocol. Method. Two hundred OLT...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2014/764234 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554159080996864 |
|---|---|
| author | Shi-Chun Lu Tao Jiang Wei Lai Yuan Liu Jing Zhang Dao-Bing Zeng Chuan-Yun Li Meng-Long Wang Dong-Dong Lin Yue Zhu You-Ping Li Ning Li |
| author_facet | Shi-Chun Lu Tao Jiang Wei Lai Yuan Liu Jing Zhang Dao-Bing Zeng Chuan-Yun Li Meng-Long Wang Dong-Dong Lin Yue Zhu You-Ping Li Ning Li |
| author_sort | Shi-Chun Lu |
| collection | DOAJ |
| description | Background. The aim of this study was to establish a hepatitis B virus (HBV) vaccination protocol among orthotopic liver transplantation (OLT) recipients under the coverage of a low-dose hepatitis B immunoglobulin (HBIG) combined with an antiviral agent prophylaxis protocol. Method. Two hundred OLT recipients were included in this study. The vaccine was injected at months 0, 1, 2, and 6. Low-dose HBIG combined with antiviral agent prophylaxis protocol was continued before reestablishment of active immunity against HBV in order to maintain a steady anti-HBs titer. Results. Active immunity against HBV was reestablished in 50 patients, for an overall response rate of 25%. Of the 50 patients, 24 discontinued HBIG without any HBV graft reinfection during a follow-up period of 26.13 ± 7.05 months. 21 patients discontinued both HBIG and antiviral agents during a follow-up period of 39.86 ± 15.47 months, and 4 patients among them appeared to be HBsAg positive. There was no recipient death or graft loss because of HBV reinfection. Conclusions. Vaccination preventing HBV reinfection for OLT recipients is feasible. The strategy withdrawal of HBIG with induction of active immunity against hepatitis B is reasonable for long-term survivors of OLT; however, discontinuation nucleoside analogues should be cautious. |
| format | Article |
| id | doaj-art-7af12bfa3f854ee59ba39195b1d424ec |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-7af12bfa3f854ee59ba39195b1d424ec2025-02-03T05:52:17ZengWileyJournal of Immunology Research2314-88612314-71562014-01-01201410.1155/2014/764234764234Reestablishment of Active Immunity against HBV Graft Reinfection after Liver Transplantation for HBV-Related End Stage Liver DiseaseShi-Chun Lu0Tao Jiang1Wei Lai2Yuan Liu3Jing Zhang4Dao-Bing Zeng5Chuan-Yun Li6Meng-Long Wang7Dong-Dong Lin8Yue Zhu9You-Ping Li10Ning Li11Department of Hepatobiliary Surgery and Liver Transplantation Program, Beijing You-An Hospital, Capital Medical University, Beijing 100069, ChinaDepartment of Hepatobiliary Surgery and Liver Transplantation Program, Beijing You-An Hospital, Capital Medical University, Beijing 100069, ChinaDepartment of General Surgery, Chengdu First People’s Hospital, Sichuan 610041, ChinaDepartment of Hepatobiliary Surgery and Liver Transplantation Program, Beijing You-An Hospital, Capital Medical University, Beijing 100069, ChinaDepartment of Hepatobiliary Surgery and Liver Transplantation Program, Beijing You-An Hospital, Capital Medical University, Beijing 100069, ChinaDepartment of Hepatobiliary Surgery and Liver Transplantation Program, Beijing You-An Hospital, Capital Medical University, Beijing 100069, ChinaDepartment of Hepatobiliary Surgery and Liver Transplantation Program, Beijing You-An Hospital, Capital Medical University, Beijing 100069, ChinaDepartment of Hepatobiliary Surgery and Liver Transplantation Program, Beijing You-An Hospital, Capital Medical University, Beijing 100069, ChinaDepartment of Hepatobiliary Surgery and Liver Transplantation Program, Beijing You-An Hospital, Capital Medical University, Beijing 100069, ChinaDepartment of Hepatobiliary Surgery and Liver Transplantation Program, Beijing You-An Hospital, Capital Medical University, Beijing 100069, ChinaKey Laboratory of Transplant Engineering and Immunology of Health Ministry, West China Hospital, Sichuan University, Chengdu, Sichuan 610044, ChinaDepartment of Hepatobiliary Surgery and Liver Transplantation Program, Beijing You-An Hospital, Capital Medical University, Beijing 100069, ChinaBackground. The aim of this study was to establish a hepatitis B virus (HBV) vaccination protocol among orthotopic liver transplantation (OLT) recipients under the coverage of a low-dose hepatitis B immunoglobulin (HBIG) combined with an antiviral agent prophylaxis protocol. Method. Two hundred OLT recipients were included in this study. The vaccine was injected at months 0, 1, 2, and 6. Low-dose HBIG combined with antiviral agent prophylaxis protocol was continued before reestablishment of active immunity against HBV in order to maintain a steady anti-HBs titer. Results. Active immunity against HBV was reestablished in 50 patients, for an overall response rate of 25%. Of the 50 patients, 24 discontinued HBIG without any HBV graft reinfection during a follow-up period of 26.13 ± 7.05 months. 21 patients discontinued both HBIG and antiviral agents during a follow-up period of 39.86 ± 15.47 months, and 4 patients among them appeared to be HBsAg positive. There was no recipient death or graft loss because of HBV reinfection. Conclusions. Vaccination preventing HBV reinfection for OLT recipients is feasible. The strategy withdrawal of HBIG with induction of active immunity against hepatitis B is reasonable for long-term survivors of OLT; however, discontinuation nucleoside analogues should be cautious.http://dx.doi.org/10.1155/2014/764234 |
| spellingShingle | Shi-Chun Lu Tao Jiang Wei Lai Yuan Liu Jing Zhang Dao-Bing Zeng Chuan-Yun Li Meng-Long Wang Dong-Dong Lin Yue Zhu You-Ping Li Ning Li Reestablishment of Active Immunity against HBV Graft Reinfection after Liver Transplantation for HBV-Related End Stage Liver Disease Journal of Immunology Research |
| title | Reestablishment of Active Immunity against HBV Graft Reinfection after Liver Transplantation for HBV-Related End Stage Liver Disease |
| title_full | Reestablishment of Active Immunity against HBV Graft Reinfection after Liver Transplantation for HBV-Related End Stage Liver Disease |
| title_fullStr | Reestablishment of Active Immunity against HBV Graft Reinfection after Liver Transplantation for HBV-Related End Stage Liver Disease |
| title_full_unstemmed | Reestablishment of Active Immunity against HBV Graft Reinfection after Liver Transplantation for HBV-Related End Stage Liver Disease |
| title_short | Reestablishment of Active Immunity against HBV Graft Reinfection after Liver Transplantation for HBV-Related End Stage Liver Disease |
| title_sort | reestablishment of active immunity against hbv graft reinfection after liver transplantation for hbv related end stage liver disease |
| url | http://dx.doi.org/10.1155/2014/764234 |
| work_keys_str_mv | AT shichunlu reestablishmentofactiveimmunityagainsthbvgraftreinfectionafterlivertransplantationforhbvrelatedendstageliverdisease AT taojiang reestablishmentofactiveimmunityagainsthbvgraftreinfectionafterlivertransplantationforhbvrelatedendstageliverdisease AT weilai reestablishmentofactiveimmunityagainsthbvgraftreinfectionafterlivertransplantationforhbvrelatedendstageliverdisease AT yuanliu reestablishmentofactiveimmunityagainsthbvgraftreinfectionafterlivertransplantationforhbvrelatedendstageliverdisease AT jingzhang reestablishmentofactiveimmunityagainsthbvgraftreinfectionafterlivertransplantationforhbvrelatedendstageliverdisease AT daobingzeng reestablishmentofactiveimmunityagainsthbvgraftreinfectionafterlivertransplantationforhbvrelatedendstageliverdisease AT chuanyunli reestablishmentofactiveimmunityagainsthbvgraftreinfectionafterlivertransplantationforhbvrelatedendstageliverdisease AT menglongwang reestablishmentofactiveimmunityagainsthbvgraftreinfectionafterlivertransplantationforhbvrelatedendstageliverdisease AT dongdonglin reestablishmentofactiveimmunityagainsthbvgraftreinfectionafterlivertransplantationforhbvrelatedendstageliverdisease AT yuezhu reestablishmentofactiveimmunityagainsthbvgraftreinfectionafterlivertransplantationforhbvrelatedendstageliverdisease AT youpingli reestablishmentofactiveimmunityagainsthbvgraftreinfectionafterlivertransplantationforhbvrelatedendstageliverdisease AT ningli reestablishmentofactiveimmunityagainsthbvgraftreinfectionafterlivertransplantationforhbvrelatedendstageliverdisease |